risks and uncertainties that are inherent in the development, testing and marketing of therapeutic hypothermia devices and the conduct of human clinical trials, including the timing, costs and outcomes of such trials, whether our efforts to launch new devices and systems and expand our markets will be successful or completed within the time frames contemplated, our dependence upon proprietary technology, our ability to obtain necessary funding, regulatory approvals and qualifications, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.
Copyright 2008 Cardium Therapeutics, Inc. All rights reserved.
Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium Therapeutics, Inc.
Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM)
are trademarks of Tissue Repair Company.
InnerCool Therapies(R), InnerCool(R), Celsius Control System(R), RapidBlue(TM), CoolBlue(TM). Accutrol(R), Temperature Control Element(R) and TCE(R) and UroCool(TM) are trademarks of InnerCool Therapies, Inc.
(other trademarks belong to their respective owners)
Page: 1 2 3 4 5 6 7 8 Related biology technology :1
. OpenClinica to Present at International Conference on Health Informatics, January 14-17, Porto, Portugal2
. Palomar and Q-MED AB Terminate International Distribution Agreement3
. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar4
. PAREXEL International to Present at the 27th Annual JP Morgan Healthcare Conference5
. ASM International N.V. and SAFC Hitech(TM) Sign Certified Manufacturer and Partnership Agreement6
. Health Robotics Announces Partnership in the Peoples Republic of China With The Devon International Group7
. Probiotic Delivery Technology Awarded Third International Patent8
. Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement9
. The International Society for Stem Cell Research Releases New Guidelines to Shape Future of Stem Cell Therapy10
. Health Robotics Announces $60M Investment by Devon International Group and ITOCHU Inc. in the CytoCare(TM) and i.v.Station(TM PENDING) Robots11
. MINRAD International, Inc. Announces Reduction in Workforce